1. Home
  2. D vs ARGX Comparison

D vs ARGX Comparison

Compare D & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dominion Energy Inc.

D

Dominion Energy Inc.

HOLD

Current Price

$68.24

Market Cap

61.4B

Sector

N/A

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$866.25

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
D
ARGX
Founded
1983
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.4B
58.4B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
D
ARGX
Price
$68.24
$866.25
Analyst Decision
Hold
Strong Buy
Analyst Count
13
19
Target Price
$65.69
$1,008.56
AVG Volume (30 Days)
3.6M
274.8K
Earning Date
05-01-2026
05-07-2026
Dividend Yield
4.27%
N/A
EPS Growth
41.39
N/A
EPS
0.69
N/A
Revenue
$16,506,000,000.00
N/A
Revenue This Year
$8.54
$44.39
Revenue Next Year
$6.51
$20.84
P/E Ratio
$100.33
$33.69
Revenue Growth
14.16
N/A
52 Week Low
$55.85
$631.74
52 Week High
$72.99
$953.58

Technical Indicators

Market Signals
Indicator
D
ARGX
Relative Strength Index (RSI) 40.64 48.12
Support Level $67.38 $822.56
Resistance Level $69.57 $938.44
Average True Range (ATR) 1.36 26.19
MACD -0.41 -4.45
Stochastic Oscillator 8.46 33.43

Price Performance

Historical Comparison
D
ARGX

About D Dominion Energy Inc.

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 31 gigawatts of electric generation capacity and more than 91,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: